<DOC>
	<DOCNO>NCT02967224</DOCNO>
	<brief_summary>Primary Objective : To demonstrate noninferiority Toujeo versus `` standard care '' basal insulin therapy measure glycosylated hemoglobin ( HbA1c ) change Secondary Objectives : - To demonstrate superiority Toujeo versus `` standard care '' basal insulin noninferiority meet , measure HbA1c change . - To compare Toujeo `` standard care '' basal insulin term patient persistence assign basal insulin therapy without intensification . - Risk hypoglycemia include incidence document symptomatic severe hypoglycemic event [ define American Diabetes Association ( ADA ] Workgroup Hypoglycemia ) . - Change fast plasma glucose ( FPG ) . - Change body weight . - Differences patient report outcomes measure Diabetes Treatment Satisfaction Questionnaire Status Change Versions ( DTSQs DTSQc ) . - Change hypoglycemic control subscale ( HCS ) - Healthcare resource utilization include hospitalization emergency department health care provider visit healthcare cost .</brief_summary>
	<brief_title>A `` Real World '' Trial Determine Efficacy Health Outcomes Toujeo Compared `` Standard Care '' Basal Insulins Insulin Naïve Patients Initiating Insulin</brief_title>
	<detailed_description>The total study duration 55 week , consist 1-week screening period site , 26-week treatment period , 26-week extension period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes insufficiently control ( HbA1c &gt; 7 % ) current ( ≥6 month ) standard care oral agent ( metformin , sulfonylurea , thiazolidinediones , DPP4 inhibitor , SGLT2 inhibitor , glinides , α glucosidase inhibitor ) without GLP1 receptor agonist , eligible basal insulin treatment , per investigator 's judgment . Exclusion criterion : HbA1c ≤7 % , upper bound . Age &lt; 18 year . Type 1 diabetes mellitus . Any clinically significant abnormality identify physical examination , laboratory test , vital sign time screen , major systemic disease result short life expectancy opinion Investigator would restrict limit patient 's successful participation duration study . Use product contain insulin since time diagnosis T2DM temporary use pregnancy hospitalization . Use product contain insulin occur within 3 month prior time screen . Use oral hypoglycemic agent note inclusion criterion , GLP 1 receptor agonist approve use insulin , investigational agent ( drug , biologic , device ) within 3 month prior time screen . All contraindication commercially available insulin therapy warnings/precautions use display respective National Product labeling product . Hypersensitivity insulin glargine Toujeo excipients . Patient Investigator Subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Pregnancy lactation . Women childbearing potential effective contraceptive method . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>